Evaluation of Two Different CMV-Immunoglobulin Regimens for Combined CMV Prophylaxis in High-Risk Patients following Lung Transplant.

Víctor Manuel Cuesta MoraPiedad UssettiAlicia de PabloDavid Fernández IturbeRosalía LaportaRodrigo AlonsoMyriam AguilarCarlos A QuezadaJosé M Cifrián

Published in: Microorganisms (2022)

Extending the adjunctive CMV-Ig prophylaxis beyond the manufacturer's recommendations up to one year does not confer additional clinical benefits regarding lung post-transplantation outcomes.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
stem cells
prognostic factors
clinical practice
type diabetes
metabolic syndrome
adipose tissue
cell therapy
bone marrow
insulin resistance
mesenchymal stem cells
skeletal muscle